Biology
Familial predisposition to CNS tumours Paediatric brain tumours arise in association with inherited syndromes listed in Table 3 . Neurofibromatosis type I (NF1) occurs due to spontaneous or inherited mutations within the NF1 gene, which encodes for a protein described as neurofibromin 1 . One of the roles of neurofibromin is as a GTPase activating protein (GAP), which is active in the same pathway of signal transduction as ras oncogene. NF1 gene is considered a 'tumour suppressor' gene. However, NF1 mutations have so far not been demonstrated in sporadic clusters of gliomas 2 . NF2 gene, present on chromosome 22q, is also considered a tumour suppressor gene as it is inactivated by deletions and mutations in a large proportion of Schwannomas 3 and meningiomas 4 associated with type 2 neurofibromatosis (NF2) as well as a large proportion of sporadic meningiomas 5 ' 6 . A further candidate meningioma gene also present on chromosome 22, may be responsible for other sporadic meningiomas 7 . Despite the histological similarity between central and peripheral PNETs the known translocation t(ll;22) in peripheral PNETs/Ewing's sarcoma has not been demonstrated in central PNETs 8 . The association of medulloblastoma with naevoid basal cell carcinoma syndrome (NBCCS) 9 suggests involvement of the NBCCS suppressor gene which is currently mapped to chromosome 9q. Loss of heterozygosity in this region has been detected in the desmoplastic sub-type of sporadic medulloblastomas 10 . The NBCCS suppressor gene on chromosome 9 may, therefore, be involved in the development of sporadic medulloblastoma. The other most frequent abnormality detected in medulloblastomas is the presence of isochromosome 17q (i) (17q) n > 12 as well as frequent loss of distal chromosome 17p sequences. Current studies of SV40 large T-antigen induced PNETs in transgenic mice 13 - 14 provide a model for the study of human PNETs of the central nervous system and may identify the involvement and role of individual genes.
Turcot's syndrome, the association of multiple colorectal adenomas and primary brain tumours, has been shown to result from germ line mutations of the APC (adenomatous polyposis coli) gene or mutations of a mismatch repair gene 15 . Such mutations have not been demonstrated in either sporadic gliomas or PNETS.
A number of chromosome/gene changes have been correlated with prognosis. The presence of (i) (17q), the presence of c-erb B2 product 16 and presence of p53 mutations may be associated with a worse prognosis in patients with medulloblastoma.
New imaging
MRI is the optimal method of detecting childhood rumours, which exhibit prolonged Tj and T 2 relaxation times. The tumour's extent is usually well demonstrated in multiplanar images and these, unlike CT images, are not degraded by overlying bone. Axial and sagittal images are most useful for the posterior fossa; the coronal plane can add further information, particularly in supratentorial tumours. CT may add information on the relation to skull bones not visible on MRI.
Gadolinium diethylenetriaminepenta-acetic acid (DTPA) is a paramagnetic MRI contrast agent, with similar distribution, after intravenous injection, to iodinated contrast used in CT. At standard tissue concentrations, gadolinium acts as a Ti shortening agent; thus, tissues containing gadolinium appear bright on Tj weighted images. Contrast enhanced MRI has the potential to assist in distinguishing, amongst other features, tumour tissue from surrounding oedema. Some small intracranial tumours, such as neuromas, may only be visualised after contrast enhanced MRI.
Spinal MRI has largely replaced myelography in the screening for leptomeningeal spread of tumours. On high Tesla MRI units, the diagnostic rate is comparable to myelography.
Angiography is rarely required for the pre-operative evaluation of paediatric CNS neoplasms.
Whilst CT and MR imaging delineate the anatomic location and extent of an intracranial neoplasm and surrounding oedema, both techniques are limited in their ability to provide data on viability or metabolic activity. It is this last characteristic that may be probed by the technique of positron emission tomography (PET).
PET scanning relies on the ability of radionuclides attached to biological substances of interest to emit positively charged particles or positrons. These collide with electrons and emit energy in the form of two gamma rays at 180° to each other. Oppositely placed detectors can quantitatively record and pictorially display the event. Computed tomography algorithms generate a brain image of metabolic activity. PET scanning may help to distinguish viable tumour from dead or metabolically inactive tissue, such as following supralethal radiation doses. Due to higher glucose metabolism, high grade tumours demonstrate higher 18 F-FDG uptake than normal grey matter or low grade gliomas 17 . The specificity of tumour diagnosis may be further improved by introducing a blood brain barrier (BBB) agent ( 82 Rb) which is excluded from normal grey matter but is taken up by gliomas where the BBB is damaged 18 .
Surgery
The current trend towards superspecialisation within the field of neurosurgery and anaesthesia is particularly beneficial for paediatric neurooncology. Most large neurosurgical units have designated paediatric neurosurgeons and the attendant specialisation in paediatric neuroanaesthesia and intensive care during the recovery period improves outcome. Proportionately more childhood brain tumours are operated on, and more operations are radical with lower morbidity than 10-20 years ago.
Corticosteroid administration (perhaps with mannitol) may sometimes obviate the need for CSF diversion in cases with obstructive hydrocephalus. This is a desirable first objective if the definitive surgical operation can then re-establish permanently the CSF flow. Hydrocephalus from midline infratentorial tumours may be temporarily treated by an external ventricular drain, as tumour removal usually re-establishes CSF flow. Tumours situated in deep midline intra-axial sites and thalamic tumours may require, a long term ventriculoperitoneal shunt.
Direct open diagnostic biopsy is preferred to stereotactic biopsy in very young children and in certain other situations. Modern imaging may provide a firm diagnosis without the need for biopsy such as optic nerve and brainstem glioma in a child with neurofibromatosis. In germ cell tumours, the radiological imaging together with raised CSF/serum markers (HCG/AFP) may also obviate the need for surgical intervention. In older children, tumour biopsy can be obtained through stereotactic surgical techniques.
Tumours on the cortical surface are approached through a regional craniotomy. Deep midline and third ventricle tumours may be approached through the anterior corpus callosum route. Intraventricular growths are approached through the dilated ventricles. Intraoperative monitoring of evoked potentials from the visual, auditory, motor and sensory cortices is used to enhance the safety of tumour resection in eloquent brain areas.
The illumination and magnification provided by the operating microscope has added an important new dimension to paediatric tumour neurosurgery. In areas of difficult access, the tumour/normal brain boundaries are much better delineated and, in conjunction with modern microsurgical tools, safer radical tumour decompressions are performed. The ultrasonic surgical aspirator or the laser may effect such resections with less trauma to the adjacent normal brain tissue than conventional instruments. The ultrasonic surgical aspirator's fine tip vibrating at 22,000 Hi breaks off microfragments of tumour whilst an irrigating channel flushes and a suction channel removes them. The narrow CO 2 laser beam accurately vaporises tumour tissue.
Radiotherapy
Radiotherapy is delivered by linear accelerators generating megavoltage X-rays. Modern facilities include multileaf collimators and portal imaging which allow more sophisticated beam shaping and verification and, therefore, reduce the amount of normal brain receiving high dose radiation. However, for most malignant brain tumours, the 'margin of safety' demands large portals that do not need the refinements of beam shaping. Nevertheless, more advanced 'blocking' (such as multileaf collimator shaping) is useful to exclude extrasensitive structures, such as the optic chiasm and hypothalamus.
Small daily dose fraction sizes (between 120-190 cGy per day) are used for the radiotherapeutic treatment of childhood brain tumours. The normal developing brain is sensitive to total radiation doses and the doses per daily treatment fraction. This applies not only to the ultimate endpoint of radiation damage -necrosis, but also to the lesser dose related morbidity of neuropsychological development, which is so relevant to the developing child.
Extensive gliomas are commonly treated with wide treatment portals with the child immobilised in an individually made restraining mask. Discrete, low grade gliomas, such as chiasmal gliomas, may be treated with a combination of fields to more effectively concentrate the radiation dose on the tumour and a limited margin. Tumours with a tendency to disseminate/metastasise via the CSF, and for whom the entire neuraxis is at risk, receive whole craniospinal radiotherapy; these include PNETs, germ cell tumours, pineoblastoma, amongst others. The whole neuraxis is treated in small daily dose fractions to doses of 3000-3500 cGy in the case of a medulloblastoma, the primary tumour area is boosted to a higher dose, e.g. 5500 cGy, either simultaneously or sequentially over a period of 6-7 weeks.
Focal stereotactic radiotherapy technology is now available to treat discrete brain tumour targets with highly localised radiotherapy in research protocols knowing that the sharp beam gradient/dose 'fall-off at the periphery of the target volume spares normal paediatric brain.
Chemotherapy of paediatric brain tumours
The concept of the blood brain barrier (BBB) which prevents the penetration of water soluble drugs into the brain, and may account for the poor chemo-responsiveness of most adult brain tumours, has delayed the introduction of chemotherapy into paediatric brain tumour management. However, it is increasingly recognised that paediatric brain tumours include clear chemosensitive tumours, such as cranial germ cell tumours and PNETs. In addition, low grade gliomas, not considered chemosensitive in adults, show clear chemo-responsiveness even though reduction in tumour size may be small. A number of single centre and multicentre prospective phase II studies of chemotherapy in childhood brain tumours are underway. Although the true value of chemotherapy can only be assessed in prospective and ideally randomised trials, the rarity of many brain tumours means that we often have to rely on information from small phase II studies.
Current use of chemotherapy in paediatric brain tumours
Chemotherapy of low grade glioma, particularly optic chiasmal glioma may allow for delay to radiation therapy. Carboplatin-based regimens 18 - 19 have shown up to 60% response rate and median time to progression of 2 years. This allows for a useful delay to radiotherapy in vulnerable young children.
Medulloblastoma is a chemosensitive tumour both in the primary and recurrent setting. Adjuvant chemotherapy given after surgery and radiotherapy (CCNU, vincristine) has been tested in two prospective randomised trials 20 -21 . These have only shown a survival benefit in children with poor prognostic features, such as locally advanced disease and disseminated disease. New regimens containing carboplatin/cisplatin, and cyclophosphamide initially tested in phase II studies are currently under investigation in randomised trials. However, phase II data have had a dominant influence on the perception of the usefulness of chemotherapy and a number of centres as well as trial groups consider the use of chemotherapy as essential. This is despite recently published negative trials of the SIOP group (SIOP II) where neoadjuvant chemotherapy with procarbazine, vincristine and methotrexate has not shown survival benefit in either good or poor prognosis patients 22 .
The use of what was essentially ineffective chemotherapy may have led to worse outcome in some patients due to delay of radiotherapy. At present the role of adjuvant chemotherapy, particularly in good risk patients, is unproven and we await the results of current randomised trials of neoadjuvant chemotherapy containing carboplatin, cyclophosphamide, etoposide and vincristine (SIOP HI).
Cranial germ cell tumours are the CNS counterparts of systemic (testicular and ovarian) germ cell tumours. As with testicular teratomas, cranial non-germinomas do not have a high cure rate with radiation alone; strategies of primary chemotherapy (using regimens proven in testicular tumours) have been adopted. These are rare tumours and the initial outcome data are only just emerging. Germinomas (equivalent to seminomas) are similarly chemosensitive. The difficulty of introducing chemotherapy into their primary treatment (in preference to radiation) is the near 100% cure rate of cranial germinomas with low dose irradiation 24 ' 25 . Chemotherapy is clearly of benefit in extensive tumours, but it cannot be substituted for wide field cranio-spinal axis irradiation as it is not effective in eradicating microscopic CSF disease. Although, a number of patients have been treated with chemotherapy alone, the safe strategy for primary chemotherapy is in combination with reduced dose irradiation.
In children with high grade glioma, the use of chemotherapy has been disappointing. A single small trial of adjuvant nitrosourea based chemotherapy had shown a survival advantage, but the overall benefit is likely to be similar to that seen in adults. Trials of new chemotherapeutic agents in this group of patients are underway.
Cranial irradiation carries a risk of late neuropsychological impairment, particularly in children under 3 years of age. New treatment strategies have evolved which rely on primary chemotherapy, at least initially, to delay radiation to the time when the brain is less likely to be damaged 26 . Although 2 year survival results of 40% and a relatively high response rate suggest efficacy of chemotherapy, the results in individual tumour types (such as PNETs) are worse than those obtained with regimens using irradiation. In any case, the survival results reported for primary chemotherapy are those of chemotherapy followed by irradiation, as the majority of patients received delayed radiotherapy. Studies of primary chemotherapy using various combinations of agents in children < 3 years of age continue world-wide
The poor outlook of children with progressive brain tumours despite treatment with surgery, radiotherapy and chemotherapy has led to the increasing use of high-dose chemotherapy and stem cell rescue. Whether this is the recourse of the destitute is the controversial nul hypothesis of the moment. The information is so far fragmentary and has yet to appear promising-high-dose chemotherapy does not appear to be effective in residual and recurrent ependymoma or in high grade glioma and is currently being evaluated in patients with recurrent medulloblastoma. Such an approach must at present be considered highly experimental with high toxicity and no known cures.
A number of new drugs are currently under test in the treatment of paediatric as well as adult brain tumours. These include the re-emergence of infusional thiotepa and the use of Temozolomide (oral Dacarbazine derivative) as chemotherapy agents and the use of the bradykinin derivative RMP-7 as an agent to locally alter BBB permeability.
Selected patients with recurrent gliomas have been treated with experimental gene therapy. The current approach involves the use of 'suicide' gene converting a pro-drug ganciclovir to an active drug within a tumour containing a transfected gene 27 . Retroviral or adenoviral vectors containing a herpes simplex (HVS) derived thymidine kinase (tk) gene are used for transfection. Currently, the vector is injected directly into the tumour using stereotactic techniques. Systemically administered ganciclovir is activated into a cytotoxic triphosphate form in tumour cells containing a HVS tk gene. Alternative experimental strategies may involve other pro-drug systems, the introduction of wildtype p53 into tumours with known p53 mutations and the use of antibody targeting. A particular candidate is the mutated version of EGF-R seen in some high grade gliomas which provides an ideal tumour specific target.
Specific tumours

Gliomas
Approximately 35% of paediatric brain tumours are supratentorial astrocytomas, which are commoner in boys. They usually present with focal neurological deficit(s) or raised intracranial pressure. Diagnosis is by modern imaging and primary treatment is surgical decompression or biopsy for diagnosis if the tumour is in a particularly eloquent brain area. It is of interest that, grade-for-grade, the long term survival of children with these tumours is better than for adults 28 . Postoperative therapy comprises radical radiotherapy and for, grade III and IV tumours, adjuvant CCNU based chemotherapy. Such radiotherapy right shifts the survival curve of patients with grade HI, IV tumours and may account for some cures amongst the grade III patients. Chemotherapy moves the survival curves slightly to the right. In order to avoid radiotherapy in young infants, recent interest has centred on the use of chemotherapy rather then radiotherapy, as primary postoperative therapy in children under 3 years of age {vide supra). There has been limited success-more so for grade HI than grade IV tumour 29 . Children with successful debulking of low grade (I-H) tumours may be initially observed without further treatment as the prognosis is often good, the late sequelae of radiotherapy of concern, and the role of chemotherapy unproven 30 . Classic cystic cerebellar astrocytoma tends to occur in the first decade of life, being slightly commoner in boys and presenting with midline cerebellar signs. The CT and operative findings are of a cystic tumour with a solid mural nodule. Following complete excision, survival is over 90% with no adjunctive therapy. The therapeutic dilemma comes when an astrocytoma in this site demonstrates diffuse/solid histology or is incompletely resected; here postoperative radiotherapy is usually recommended.
Ependymoma comprise an interesting subset of gliomas (7% of all paediatric brain tumours), often, but not always, arising in periventricular locations. Two-thirds of intracranial ependymomas arise in the posterior fossa. Presenting and radiological signs are similar to those of astrocytomas and medulloblastomas and surgical debulking (preceded by ventriculo peritoneal shunting where presenting obstructive hydrocephalus demands) is first therapy ideally by complete excision. A characteristic which differentiates higher grade ependymoma from astrocytoma is that proclivity for CSF dissemination although controversy surrounds the need for neuraxis radiotherapy prophylaxis.
Optic nerve gliomas have a peak incidence in the first 5 years of life; 75% appear by age 10 years and 90% by age 20 years. They present with failing vision due to involvement of optic nerve or chiasm. Progressive tumours lying within one optic nerve and anterior to the chiasm are diagnosed by MRI and if epileptic may be excised. With typical CT or MR images and in the presence of other stigmata of type I neurofibromatosis, biopsy is not mandatory. Surgery to debulk the larger tumours may be considered sensible, but not where this would risk worsening the clinical, visual or neuroendocrine symptom complex. Radiotherapy has been a standard and successful therapy 31 ; recently, carboplatin-based chemotherapy has been shown to produce responses and might well be chosen as first therapy in infants or very young children 19 . For children with gliomas, who relapse after first radical therapy, the future is bleak. Experimental therapies include focal stereotactic radiation techniques for localised relapses and high dose chemotherapy 32 but none are currently curative.
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There remains one group of gliomas which are always considered apart and provide a particular problem. Brain stem gliomas comprise 15-20% of paediatric CNS tumours, occur predominantly in the age range 5-15 years and with equal sex incidence. Clinical presentation is usually due to obstructive hydrocephalus or progressive brainstem signs. CT/MR imaging is usually highly accurate although, where safe, stereotactic biopsy will give the definitive diagnosis and glioma grading (of prognostic import). Patients with enhancing central hypodense apparently cystic tumours on CT scan usually have worse prognosis. Patients with multiple cranial nerve palsies have tumours extensive within the brainstem, also a poor prognostic sign 33 . Brain stem tumours are rarely amenable to radical surgery and treatment is by primary radiotherapy. Notwithstanding this, the majority of patients will die within 2-3 years, only perhaps 20-30% of low grade tumour patients surviving longer. Although there was some interest in high total dose, hyperfractionated radiotherapy, the synthesis of the trials' data do not support its use 34 , and there are fewer positive data to support the use of chemotherapy than in supratentorial astrocytoma.
Medulloblastoma/PNET
The classic paediatric cerebellar medulloblastoma arises in the vermis of the cerebellum, has a peak incidence at 5 years and a tendency to spread (10-40% of cases at presentation) via CSF pathways. It is now recognised that the primitive neurectodermal cell origin of medulloblastoma is also the origin of other paediatric brain tumours (PNETs) previously referred to as cerebral neuroblastoma. Histologically the tumours comprise small round cells with large nuclei, staining positively for NSE and not for glial fibrillary acidic protein. However PNETs may demonstrate glial or ependymal differentiation. PNETs are sensitive to chemotherapy and radiotherapy and, with current treatment programmes, overall cure rates of 50% or more are expected. The time period for risk of relapse may be many years.
Although PNET comprises 20-25% of all paediatric brain tumours presenting in Western neurosurgical centres over the last 40 years, there is recent evidence that the incidence is falling 35 . A possible explanation is suggested to be periconceptional dietary supplements of folates and vitamins hypothesised to protect against neural tube defects.
Following diagnosis, staging and initial radical surgery, postoperative neuraxis radiotherapy and high dose radiotherapy to the primary site has been standard best treatment. Similar chemotherapy given before radiotherapy was not demonstrated to be useful 38 , although with the proven better efficacy of more modern (platinum based) chemotherapy 39 , many groups are now restudying primary (pre-radiation) chemotherapy, particularly in very young children and infants for whom there are now accumulating data to suggest that neuraxis radiotherapy can often be delayed by such primary chemotherapeutic treatment 40 . If radiotherapy neuraxis can safely be delayed in young children it would reduce the late neuropsychological sequelae of radiotherapy which are a major concern.
Medulloblastoma/PNET are sensitive to platinum based therapy 39 -41 , a sensitivity that exceeded that observed with CCNU/vincristine chemotherapy in patients treated with measurable (surgically unresectable) relapse. It was observations such as these that led to the reintroduction of chemotherapy (adjuvant and immediate postoperative) for primary treatment programmes. Etoposide complements platinum in combination chemotherapy regimens 41 -42 . Current trials of adjuvant platinum based chemotherapy and longer term follow up of infants treated with primary chemotherapy will provide information on the appropriate treatment strategies.
Cranial germ cell tumours
The pineal and suprasellar region are the site of isolated extragonadal germ cell tumours (GCT), which arise in the absence of testicular or other systemic GCTs. Germinoma, which is histologically identical to testicular seminoma, represents over 50% of all tumours occurring in the pineal region. Non-germinomatous (NG) GCTs consist of variants of malignant as well a benign teratomas. As GCTs at other sites they may secrete tumour markers with elevated AFP and/or high level of HCG considered as diagnostic of NG GCTs.
Cranial GCTs have a propensity for CNS spread via the CSF pathway. The overall risk of dissemination is 10-20% 43 . As opposed to other cranial tumours, disease can spread systemically via CSF shunts. Initial staging of cranial GCTs should include marker assessment (serum and CSF), spinal MRI and CSF cytology.
Germinomas have been traditionally treated with cranio-spinal axis irradiation with excellent long-term results and only 5-6% risk of recurrence 24 ' 25 . There are no clear predictors of outcome. However, the presence of tumour cells in the CSF is associated with higher risk of CSF seeding at presentation and at relapse 44 .
The high cure rate with little long-term toxicity make changes to treatment difficult. Based on the known radiation sensitivity of seminoma, the dose of radiotherapy is being gradually reduced. So far, the reduction of tumour dose from 50 to 40 Gy has retained treatment efficacy 45 . Further reduction of the tumour dose is being tested in current prospective studies. Spinal dose may also be reduced and trials looking at its omission in some patients are being explored.
Cranial germinomas are also highly chemosensitive tumours. This has led to approaches using primary chemotherapy 46 . The aim is to allow for lower radiation dose and in some instances it may be possible to avoid RT altogether. However, at present, the use of chemotherapy alone is unproven and it is a potentially risky strategy with no known long-term outcome and toxicity. Nevertheless, the use of primary chemotherapy combined with reduced radiotherapy dose is being explored, particularly in large and extensive tumours. The European co-operative group (SIOP) is otherwise continuing to treat children with small cranial germinomas with wide-field radiotherapy alone.
The results of treatment of non-germinomatous GCTs with craniospinal irradiation are disappointing. Despite high dose radiation to the pineal region, many patients recur 24 . Based on the analogy of chemocurability in testicular non-seminomatous GCTs, the strategies of chemotherapy as the primary treatment modality are being explored. The results from small series suggest that this may be a more effective approach than radiotherapy alone, although this contention remains unproven at present. The current consensus on the management of NG GCTs is primary chemotherapy followed by radical surgery/radiotherapy.
Parasellar tumours
The suprasellar region adjacent to the third ventrical is a site for a number of brain tumours in children. These include germ cell tumours, optic chiasmal gliomas and craniopharyngiomas. Langerhans's cell histiocytosis (LCH) may also mimic a tumour in the suprasellar region. Children with a tumour in this region may present with hydrocephalus due to obstruction of CSF outflow from the third ventricle as well as a number of syndromes due to hypothalamic-pituitary dysfunction, diencephalic syndrome, visual impairment and mental disturbances. Endocrine syndromes may include precocious puberty as well as diabetes insipidus and pituitary hormone deficiency.
Craniopharyngiomas are benign neoplasms arising from epithelial rests of Ratchke's pouch in the suprasellar region. They are partly solid and partly cystic tumours lined by stratified squamous epithelium. They compress and closely adhere to adjacent structures. CT and MRI scan show a partly cystic and partly solid suprasellar mass with calcification in the cyst wall.
Management includes surgery and radiotherapy 47 . Although excision leads to rapid relief of compressive symptoms, it may not be curative. Total excision is difficult as craniopharyngioma is firmly adherent to surrounding structures and complications include hypothalamic damage and severe endocrine deficiency. Despite apparent complete resection, recurrence rate is of the order of 10-20% 47 > 48 . Following incomplete surgery alone, the risk of recurrence is high ranging from 65-75%. Radiotherapy is highly effective in controlling the growth of craniopharyngioma and the recommended dose is 50 Gy in 30-33 daily fractions using a localised treatment technique. Following conservative surgery and radiotherapy, the recurrence rate is 10-20%, with 80-100% 5 year and 70-90% 10 year survival with little short and long term morbidity Despite considerable debate about the most appropriate treatment approach, it is clear that in children over 4 years of age the best tumour control and least long-term morbidity is achieved with the policy of conservative surgery followed by local radiotherapy.
Although new techniques of radiation, such as stereotactic radiotherapy/radiosurgery, are being explored in the treatment of craniopharyngiomas, the tumours are rarely of appropriate size for such small treatment volumes and single fraction radiosurgery carries an unacceptably high risk of damage to the surrounding normal structures. The technique of stereotactically guided conformal radiotherapy using conventional fractionation may become the treatment technique of choice in this situation.
